Alex Aviles/iStock via Getty Images Sanofi ( NASDAQ: SNY ) said that new phase 2 data indicates that its candidate rilzabrutinib led to a significant decline in loss of asthma control events compared to placebo. Results showed that at week 12, high and low dose rilzabrutinib led to, respectively, a 36% and 25% relative risk reduction in loss of asthma control events. In addition, other improvements in asthma symptoms were seen.
There were no instances of cytopenia, hemorrhagic events, or atrial fibrillation, and no imbalance in liver function tests. In the study , patients were randomized to receive rilzabrutinib 800 mg or 1200 mg daily or placebo in addition to inhaled corticosteroid plus long-acting β2 adrenergic agonist therapy that was withdrawn over 12 weeks. Sanofi ( SNY ) said the results support advancing the BTK inhibitor into phase 3.
More on Sanofi Sanofi Q1: Wait And See For Now (Downgrade) Sanofi: Q1 Earnings Reflect Growth And Strategic Acquisitions (Rating Upgrade) Sanofi 2024 Q1 - Results - Earnings Call Presentation Sanofi teams up with Formation Bio, OpenAI on AI-driven drug development Sanofi gains license for ex-U.S. rights to Fulcrum muscular dystrophy candidate.